Awesome post Plotinus. I too find it very intriguing that Cyrus came to CytoDyn leaving his position as Chief Business Officer at Nimble Therapeutics, having previously worked at Neuvogen as VP of Corporate Development. At Neuvogen, he had worked with Denny Lanfear on the Board of Directors at Neuvogen, who also happens to be CEO of Coherus Biosciences. Neuvogen and Coherus are both in California. Coherus owns Toripalimab which is a PD-1 inhibitor which Coherus already submitted BLA for which FDA should respond to by 12/23/22.

Here are some pertinent pages:
https://neuvogen.com/about-us/#1608127364370-9ee6f98c-e66c

https://www.coherus.com/products-and-pipeline/

Quote:

---

Under his leadership, Coherus BioSciences was transformed from an unfunded startup into the industry’s leading pure play biosimilar company, with over $1.25 billion in funding being raised since its inception.

---

I too believe Cyrus must believe strongly in Leronlimab and must believe he has what it takes to get this molecule to market. He has the experience in working with Denny Lanfear, watching what he did at Coherus and how the biosimiilar market works and what needs to happen in order to bring Leronlimab to the forefront. I too think teamwork will be paramount and I feel CytoDyn will be at the center acting as quarterback calling the plays on how to progress the ball down the field.